At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 31 enrolled
Drug / intervention
Psilocybin (0.25mg/kg) +1 moredrug
Likely dose
Psilocybin (0.25mg/kg)from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Psilocybin Treatment in Obsessive-Compulsive Disorder: a Preliminary Efficacy Study and Exploratory Investigation of Neural Correlates.
In Brief
A Phase 1 clinical trial evaluating Psilocybin (0.25mg/kg) and Niacin (250mg) for Obsessive-Compulsive Disorder. Completed, enrolled 31 participants across 1 site.
Detailed Summary
This study aims to investigate the effects of oral psilocybin on OCD symptomatology and provide the first evidence of the neural mechanism that may mediate psilocybin's purported therapeutic effects on OCD.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObsessive-Compulsive Disorder
CountriesUnited States
Timeline
Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedNov 2017
Enrollment StartNov 2018
Primary CompletionJul 2024
TodayJul 2026
First PostedNov 29, 2017
Enrollment StartNov 13, 2018
Primary CompletionJul 25, 2024
TodayJul 2, 2026
Enrollment to primary: 5.7 yearsPosted 8.6 years ago
Interventions
Psilocybin (0.25mg/kg)drug
Psilocybin is a naturally occurring hallucinogenic ingredient found in some varieties of mushrooms that can be produced synthetically. It is considered to be a serotonergic psychedelic.
Niacin (250mg)drug
A medication used to treat high cholesterol, triglyceride levels, and niacin deficiency.